931399-19-8

Basic information

• Product Name: N-[[1-(2-Cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxo-1,2-dihydro-3-quinolinyl]carbonyl]glycine
• Synonyms: GSK360A;N-[[1-(2-Cyclopropylethyl)-6-fluoro-1,2-dihydro-4-hydroxy-2-oxo-3-quinolinyl]carbonyl]glycine;N-[[1-(2-Cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxo-1,2-dihydro-3-quinolinyl]carbonyl]glycine
• CAS NO: 931399-19-8
• Molecular Formula: C17H17FN2O5
• Molecular Weight: 348.3256832
• Product Categories: Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 931399-19-8.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• Solubility: Acetone (Slightly, Heated), DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: N-[[1-(2-Cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxo-1,2-dihydro-3-quinolinyl]carbonyl]glycine(CAS DataBase Reference)
• NIST Chemistry Reference: N-[[1-(2-Cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxo-1,2-dihydro-3-quinolinyl]carbonyl]glycine(931399-19-8)
• EPA Substance Registry System: N-[[1-(2-Cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxo-1,2-dihydro-3-quinolinyl]carbonyl]glycine(931399-19-8)

Safety Data

• Hazardous Substances Data: 931399-19-8(Hazardous Substances Data)

Usage

Chemical Properties

Beige Solid

Uses

GSK360A orally active HIF-PHD inhibitor. GSK360A exerts systemic and local effects by stabilizing HIF-1α signaling and improves long-term ventricular function, remodeling, and vascularity in a model of established ventricular dysfunction. These findings suggest that GSK360A may be suitable for the treatment of post-MI remodeling and heart failure.

Upstream product

• 931399-20-1 ethyl 1-(2-cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxo-1,2-dihydro-3-quinolinecarboxylate 
• 6000-44-8 sodium glycinate 

Relevant articles and documents

PROLYL HYDROXYLASE ANTAGONISTS

This invention relates to certain 2-[(quinolin-3-yl)carbonyl]aminoacetic acid derivatives of formula (I), where the various groups are defined herein, and which are useful in treating anemia.